The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization (EUA) allowing the Pfizer-BioNTech COVID-19 Vaccine to be distributed in the U.S. The FDA’s Vaccines and Related Biological Products Advisory Committee discussed efficacy and potential issues arising from issuing the EUA on December 10, concluding that the vaccine is effective in preventing COVID-19 and potential benefits of the vaccine outweigh its potential risks. The Advisory Committee met again on December 17 to discuss a potential EUA for the Moderna COVID-19 vaccine candidate and the FDA is expected to issue the EUA at a later date.
